Bayer Aktiengesellschaft (BAYRY)
OTCMKTS
· Delayed Price · Currency is USD
7.51
-0.02 (-0.27%)
Jun 6, 2025, 10:50 AM EDT
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 13.74B EUR in the quarter ending March 31, 2025, a decrease of -0.20%. This brings the company's revenue in the last twelve months to 46.58B, down -0.92% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
46.58B EUR
Revenue Growth
-0.92%
P/S Ratio
0.59
Revenue / Employee
514.19K EUR
Employees
90,587
Market Cap
29.73B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Bayer Aktiengesellschaft News
- 23 hours ago - Bayer raised to Buy at Goldman after hitting bottom of negative earnings revision cycle - Seeking Alpha
- 1 day ago - Bayer Crop Science delegation visits ISARC - The Times of India
- 2 days ago - Bayer subsidiary gains worldwide rights to develop cancer asset VVD-214 - Seeking Alpha
- 2 days ago - Bayer gets FDA nod for Nubeqa in advanced prostate cancer - Seeking Alpha
- 2 days ago - Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor - Business Wire
- 3 days ago - Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress - Business Wire
- 9 days ago - Bayer says new lung cancer therapy granted FDA priority review - Seeking Alpha
- 14 days ago - Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea - Seeking Alpha